We Need to Talk (On-demand Webcast)

Sponsored by:

The workplace is a complex, diverse environment. Among colleagues, communication behavior likely is the most important individual trait driving interaction. Whether attempting to reach consensus, solicit support for a deliverable or simply succeed at requesting budget, this webcast explores internal communication know-how and persuasion strategies to improve cooperation and effectiveness at work.

Learning Levels: 

Intermediate to advanced

Learning Objectives

Upon the webcast's conclusion, you will be able to: 

  • Identify communication behaviors and needs
  • Match communication strategies and tactics to these individual traits
  • Appreciate why effective persuasion is essential to workplace efficiency
  • Understand the bases of influence to be more persuasive
  • Utilize the communication tactics learned

Who Should Attend?

Regulatory professionals of all levels and backgrounds who are looking to improve their or their team’s internal communication skills.


Frank Carillo, CEO, ECG Inc.

Frank Carillo is responsible for ECG’s overall pharmaceutical and healthcare specialty practice management. He has worked with clients that must present New Drug Applications to FDA Advisory Committees for approval and commercial release. Carillo and his partners consult and coach pharmaceutical company CEOs and senior executives, healthcare providers,academic experts, legislators and consulting firms on strategies to address this volatile national issue. Carillo has been instrumental in clients’ success at numerous FDA Advisory Committee Meetings, generating a powerful record of approvals

Chi Li, PhD, MBA, RAC, global head – hematology, Bayer HealthCare Pharmaceuticals Inc.

Chi Li currently is the global head of hematology within the global regulatory affairs organization at Bayer HealthCare Pharmaceuticals Inc. He oversees a portfolio of marketed and investigational drugs and manages a group of regulatory colleagues based in the US, Germany and Beijing.  Li has 15 years of experience in global regulatory affairs and has worked on more than 25 drug development programs in several therapeutic areas. The recent registration successes under his leadership include the approvals of KOVALTRY, BETACONNECT and OLYSIO.  Li previously worked for Bristol-Myers Squibb, Pfizer and Johnson & Johnson in regulatory affairs with increasing responsibilities.  Li holds a PhD in organic chemistry from Purdue University and earned his RAC.  He has a number of peer-reviewed publications and patents to his credit.